Bronchopulmonary neuroendocrine tumors

Gustafsson, Björn; Kidd, Mark; Chan, Anthony K.C.; Malfertheiner, Maximilian; Modlin, Irvin M.

doi:10.1002/cncr.23542

Cited by 445 publications

(426 citation statements)

References 123 publications

Supporting

Mentioning

340

Contrasting

Unclassified

Order By: Relevance

“…Differences in metastatic potential to regional lymph nodes, liver, and bone account for major differences in behavior of TCs and ACs (Beasley et al 2004), with radical surgery offering the best chance to survive these tumors (Filosso et al 2002a). Because susceptibility to chemotherapy agents of metastatic LCs may be reduced due to low response rates and serious side effects, multimodality strategies have been developed (Gustafsson et al 2008). Indeed, somatostatin receptors (SSTRs) can be expressed in LCs (Righi et al 2010) and may be used for both their diagnosis and therapy (Pelosi et al 2006).…”

mentioning

confidence: 99%

Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids

Giandomenico¹,

Tao²,

Grimelius³

et al. 2013

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Somatostatin receptors (SSTRs) may be used in lung carcinoids (LCs) for diagnosis and therapy, although additional targets are clearly warranted. This study aimed to investigate whether olfactory receptor 51E1 (OR51E1) may be a potential target for LCs. OR51E1 coding sequence was analyzed in LC cell lines, NCI-H727 and NCI-H720. OR51E1 transcript expression was investigated in LC cell lines and frozen specimens by quantitative real-time PCR. OR51E1, SSTR2, SSTR3, and SSTR5 expression was evaluated by immunohistochemistry on paraffin-embedded sections of 73 typical carcinoids (TCs), 14 atypical carcinoids (ACs), and 11 regional/distant metastases and compared with OctreoScan data. Immunohistochemistry results were rendered semiquantitatively on a scale from 0 to 3, taking into account the cellular compartmentalization (membrane vs cytoplasm) and the percentage of tumor cells (!50 vs O50%). Our results showed that WT OR51E1 transcript was expressed in both LC cell lines. OR51E1 mRNA was expressed in 9 out of 12 TCs and 7 out of 9 ACs (PZNS). Immunohistochemically, OR51E1, SSTR2, SSTR3, and SSTR5 were detected in 85, 71, 25, and 39% of TCs and in 86, 79, 43, and 36% of ACs respectively. OR51E1 immunohistochemical scores were higher or equal than those of SSTRs' in 79% of TCs and 86% of ACs. Furthermore, in the LC cases where all SSTR subtypes were lacking, membrane OR51E1 expression was detected in 10 out of 17 TCs and 1 out of 2 ACs. Moreover, higher OR51E1 immunohistochemical scores were detected in 5 out of 6 OctreoScan-negative LC lesions. Therefore, the high expression of OR51E1 in LCs makes it a potential novel diagnostic target in SSTR-negative tumors.

show abstract

mentioning

confidence: 99%

Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids

Giandomenico¹,

Tao²,

Grimelius³

et al. 2013

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

show abstract

“…AC patients status post resection continue to have a lower 5-and 10-year survival rate compared to TC patients due to increased risk of metastases and recurrence (2,4,5). The increased rate of nodal involvement with ACs warrants lymph node dissection even in patients with N0 disease (11). Current guidelines created by the Fleischner Society ( Table 1), direct radiologists for follow up of incidental pulmonary nodules, which is often how NETs are discovered (12).…”

Section: Discussionmentioning

confidence: 99%

Do we really care about incidental lung nodules?—Review of atypical lung carcinoid and a proposal for systematic patient follow up

Motiwala

Bansal

Goyal

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

This article describes a nonsmoker female with enlarging solitary pulmonary nodule who was initially lost to follow up, subsequently operated and with final pathology revealing atypical lung carcinoid. This case stress on the schematic follow up of these incidentally detected pulmonary nodules. Inspired from the mandatory lay mammography report letters recommended by ACR, this article proposes sending lay letters to patients for pulmonary nodule follow up, directly from the Radiology Department to reinforce the importance of timely follow up, which will complement the information provided to the patient from their primary care physician or pulmonologist's office.

show abstract

“…Incidence in 2003 was 1.57 per 100,000, and on the rise. Survival at 5 years was 88% for typical carcinoid tumors with scarce growth (44).…”

Section: Prognosis and Survivalmentioning

confidence: 99%

Neuroendocrine tumors: fascination and infrequency

Lorenzo

2009

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

In this article, I review and update of gastro-entero-pancreatic neuroendocrine tumors, which so much fascination have risen among healthcare providers on grounds of their infrequency, hormonal syndromes, and high survival rate, is performed based on references from the past fifteen years. DEFINITIONNeuroendocrine tumors (NETs) or gastroenteropancreatic endocrine tumors (GEPETs) (2% of all gastrointestinal tumors) have their origin in tissues derived from the neural crest, neuroectoderm, and endoderm; 60-70% are carcinoid tumors, and 20-40% are found in the pancreas (NEPTs) ( Tables I and II). Gastrointestinal tract endocrine tumors other than carcinoid tumors may be gastrinomas, enteroglucagonomas, somatostatinomas, or non-functioning neuroendocrine tumors. Many of the data discussed herein have been taken from prior reviews (1-5). INCIDENCEIn necropsies 0.5-1.5%, or even up to 5%, are NEPTs (1-2), many of them silent. They represent 1-3% of all pancreatic neoplasms.In Europe, in the one community-based study carried out thus far, incidence is smaller than one case per 100,000/year -specifically, 0.32 per 100,000/year for carcinoid tumors and 0.2 per 100,000/year (2 per million/year) in the pancreas (6). Insulinoma and gastrinoma, the most common types, have an incidence of 1 new case per million people and year. Glucagonoma and somatostatinoma are least common (1 per 20 and 40 million/year, respectively) (Table II).Carcinoids are twice as common in Afroamerican patients than among Caucasians (7).In the USA (8), incidence approaches 5 per million/year for NEPT, 1.8 in women and 2.6 in men, but is increasing and may well reach 10 per million people/year, with a higher frequency between 40 and 60 years of age, and in women.In our country the incidence of NEPT may be 0.08 per 100,000 inhabitants/year, or 1 new case every two years in Hospitalet de Llobregat (Barcelona). GENETICSTumors may be sporadic, particularly carcinoids, or may develop in association with dominant autosomic syndromes (2) -locus 11q13 for MEN-1 -including multiple REV ESP ENFERM DIG (Madrid) Vol. 101. N.°3, pp. 195-208, 2009 Received: 28-12-08. Accepted: 08-01-09.

show abstract

Bronchopulmonary neuroendocrine tumors

Cited by 445 publications

References 123 publications

Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids

Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids

Do we really care about incidental lung nodules?—Review of atypical lung carcinoid and a proposal for systematic patient follow up

Neuroendocrine tumors: fascination and infrequency

Contact Info

Product

Resources

About